Rucaparib for metastatic castration-resistant prostate cancer associated with homologous recombination deficiency

Rucaparib is currently in clinical development for the treatment of metastatic prostate cancer (cancer that has spread beyond the prostate) that is resistant to hormone therapy and associated with a homologous recombination deficiency (HRD), which is when your body is unable to repair double strand breaks in DNA. Metastatic prostate cancer that is resistant to hormone therapy is known as metastatic castration-resistant prostate cancer (mCRPC). Patients can progress on initial treatment such as androgen receptor–directed therapy and taxane chemotherapy, and subsequent treatment options are limited, thus more effective treatments are needed.